| 18.44 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.59 | 1-year : | 25.22 |
| Resists | First : | 18.48 | Second : | 21.59 |
| Pivot price | 18.44 | |||
| Supports | First : | 18.08 | Second : | 17.82 |
| MAs | MA(5) : | 18.44 | MA(20) : | 18.44 |
| MA(100) : | 17.99 |
MA(250) : | 13.12 |
|
| MACD | MACD : | 0.02  |
Signal : | 0.03 |
| %K %D | K(14,3) : | 92.42 | D(3) : | 92.42 |
| RSI | RSI(14): 73.35 | |||
| 52-week | High : | 18.48 | Low : | 5.8 |
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
Tue, 14 Sep 2021
UPDATE: Pfizer and Trillium: How a $25M investment led to a $2.3B buyout - Fierce Biotech
Tue, 24 Aug 2021
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion - Yahoo Finance
Mon, 23 Aug 2021
Why Trillium Therapeutics Stock Is Skyrocketing Today - The Motley Fool
Mon, 23 Aug 2021
Trillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billion - MarketWatch
Mon, 23 Aug 2021
Pfizer to buy cancer drug developer Trillium in $2.3 bln deal - Reuters
Mon, 23 Aug 2021
Pfizer to Acquire Trillium Therapeutics Inc. - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 81.8 (%) |
| Shares Short | 2,310 (K) |
| Shares Short P.Month | 2,810 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | -0.96 |
| EPS Est This Year | -4.14 |
| EPS Est Next Year | -2.75 |
| Book Value (p.s.) | 2.32 |
| Profit Margin | 0 % |
| Operating Margin | -118642 % |
| Return on Assets (ttm) | -15.61 % |
| Return on Equity (ttm) | -29.91 % |
| Qtrly Rev. Growth | -91.31 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -36.89 |
| PEG Ratio | 0 |
| Price to Book value | 7.91 |
| Price to Sales | 45027.9 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|